Considering the high prevalence and the complex pharmacological management of immune-
mediated inflammatory diseases (IMIDs), the search for new therapeutic approaches for their …

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection has caused a
global pandemic since late 2019 that resulted in more than 360 million population infection …

The lung is the primary site of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-
2)-induced immunopathology whereby the virus enters the host cells by binding to …

Background Treatment of acute respiratory distress syndrome (ARDS) associated with
COronaVIrus Disease-2019 (COVID-19) currently relies on dexamethasone and supportive …

Mesenchymal stromal cells (MSC) have shown potential efficacy in both animal and human
trials of acute respiratory distress syndrome (ARDS). Especially during the COVID-19 …

During the pandemic of severe respiratory distress syndrome coronavirus 2 (SARS-CoV2),
many novel therapeutic modalities to treat Coronavirus 2019 induced disease (COVID-19) …

Inflammatory response in COVID-19 contributes greatly to disease severity. Mesenchymal
Stem Cells (MSCs) have the potential to alleviate inflammation and reduce mortality and …

Transplantation of umbilical cord blood (UCB) is an attractive alternative source of
hematopoietic stem cells (HSCs). The unique properties of cord blood and its distinct …

The severe respiratory consequences of the coronavirus disease 2019 (COVID-19)
pandemic have prompted the urgent need for novel therapies. Cell-based therapies …

Despite global efforts to establish effective interventions for coronavirus disease 2019
(COVID-19) and its major complications, such as acute respiratory distress syndrome …